Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P0EI
|
|||
| Former ID |
DIB005698
|
|||
| Drug Name |
PRLX93936
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1/2 | [1] | |
| Company |
Prolexys Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-dependent anion-selective channel 3 (VDAC3) | Target Info | Modulator | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| Parkinson's disease | ||||
| Huntington's disease | ||||
| Hepatitis B | ||||
| HTLV-I infection | ||||
| Viral carcinogenesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01695590) Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma. U.S. National Institutes of Health. | |||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.